Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by autoantibody production and immune complex deposition that result in tissue inflammation and damage[@b1]. SLE-related glomerulonephritis (GN), also known as lupus nephritis (LN), is one of the most common and severe complications of SLE because of the risk of cardiovascular disease and end-stage renal disease[@b2].

NZB, (NZB × NZW) F1 hybrid, BXSB/MpJ-*Yaa* (BXSB-*Yaa*), and MRL/MpJ-*lpr* mice are commonly used as spontaneous SLE models[@b3]. These strains develop systemic autoimmune diseases characterized by increased serum autoantibody levels and vasculitis, in addition to GN that is similar to human LN[@b3]. Recently, we described the pathological interactions between the immune-associated genes on chromosome 1 and the genetic locus on chromosome Y in the glomerular pathogenesis of BXSB-*Yaa* mice[@b4]*.* BXSB-*Yaa* mice carry a genetic mutation located on the Y chromosome, namely, Y-linked autoimmune acceleration (*Yaa*). The severity of GN is greater in males than in females because of the *Yaa* mutation[@b3][@b4][@b5][@b6]. The *Yaa* mutation is a translocation from the telomeric end of the X chromosome to the Y chromosome. The duplicated segment plays a crucial role in the activation of auto-reactive B cells, thereby contributing to the *Yaa*-mediated enhancement of the autoimmune phenotype in male BXSB-*Yaa* mice[@b7]. The *Yaa* locus contains several immune-associated genes, including Toll-like receptor (TLR) family members[@b7].

TLRs are expressed on the plasma membrane or intracellular vesicular membrane of hematopoietic and non-hematopoietic cells[@b8]. They have been characterized as innate immune sensors that recognize danger signals arising from pathogen-associated molecular patterns (PAMPs), including flagellin, lipopolysaccharide (LPS), and nucleic acids derived from bacteria, mycobacteria, mycoplasma, fungi, and viruses[@b8]. Previous studies have identified 12 members of the TLR family in mice (TLR1--9 and TLR11--13) and 10 in humans (TLR1--10)[@b8]. When activated by their own pathogenic ligands, TLRs enhance inflammatory cytokine expression mainly through the NF-κΒ pathway to provide host defence[@b8].

Interactions between TLRs and their endogenous ligands have been shown to play important roles in the pathogenesis of non-infectious injury[@b9][@b10][@b11][@b12]. Mersmann *et al.* have suggested that endogenous high-mobility group box 1 (HMGB1) contributes to myocardial injury through the activation of TLR2 signalling[@b11]. Shichita *et al*. have demonstrated a pathological interaction between endogenous peroxiredoxin and TLR2 or TLR4 on macrophages in ischemic brain injury[@b12]. Endogenous TLR ligands are called danger-associated molecular patterns (DAMPs) and are thought to be danger signals that relay the presence of tissue injury to immune cells or local intrinsic cells, thereby inducing local tissue inflammation and damage[@b9][@b10][@b11][@b12].

Experimental and clinical studies have shown that TLRs expressed in intrinsic renal cells are involved in the pathogenesis of several kidney diseases[@b13][@b14][@b15][@b16][@b17][@b18]. In particular, TLR4, TLR5, and TLR11 in tubular epithelial cells play an important role in the pathogenesis of urinary tract infections and sepsis-induced renal failure[@b14][@b15][@b16]. The activation of TLR2 or TLR4 by DAMPs in tubular epithelial cells contributes to the progression of kidney ischemia-reperfusion injury and subsequent renal fibrosis[@b17][@b18]. This suggests that activation of the TLR signalling pathway plays a crucial role in renal tubulointerstitial injury in various pathological conditions. However, little is known about the involvement of TLRs in glomerular diseases. In the present study, we focused on LN and found marked upregulation of *Tlr8* and its downstream cytokines in the glomeruli of BXSB-*Yaa* mice.

Results
=======

Clinical parameters of BXSB-*Yaa* mice
--------------------------------------

With regard to the clinical index of the systemic autoimmune condition, serum anti-double-strand DNA (dsDNA) antibody levels were higher in BXSB-*Yaa* mice than in BXSB/MpJ-*Yaa*^+^ (BXSB) mice at 2 and 4 months of age ([Table 1](#t1){ref-type="table"}). There were no differences in the indices of renal function, including serum blood urea nitrogen (sBUN) and serum creatinine (sCre), between the strains at any age. However, urinary albumin-to-creatinine ratio (uACR) levels, which serve as an index of glomerular dysfunction, were higher in BXSB-*Yaa* mice than in BXSB mice at 4 months of age ([Table 1](#t1){ref-type="table"}).

Glomerular histopathology in BXSB-*Yaa* mice
--------------------------------------------

Glomerular histopathology was examined in kidney sections stained with periodic acid-Schiff (PAS) ([Fig. 1a--d](#f1){ref-type="fig"}) or periodic acid methenamine silver (PAM) ([Fig. 1e--h](#f1){ref-type="fig"}) at 2 and 4 months of age. No glomerular lesions were observed at any age in BXSB mice ([Fig. 1 a, b, e, and f](#f1){ref-type="fig"}) or at 2 months in BXSB-*Yaa* mice ([Fig. 1c and g](#f1){ref-type="fig"}). In contrast, at 4 months of age, BXSB-*Yaa* mice developed GN, which was characterized by glomerular hypertrophy, increases in mesangial cell number and the mesangial matrix, thickening of the glomerular basement membrane (GBM), and spike-like structures on the GBM ([Fig. 1d and h](#f1){ref-type="fig"}).

Glomerular expression of TLR family members and activation of TLR-mediated signalling in BXSB-*Yaa* mice
--------------------------------------------------------------------------------------------------------

To determine which TLR members are associated with GN pathogenesis, we first examined the expression of 12 TLR family genes in the isolated glomeruli of BXSB-*Yaa* mice at 4 months of age ([Fig. 2a](#f2){ref-type="fig"}). The glomerular expression of *Tlr1*, *2*, *7*, *8*, *9*, and *13* was higher in BXSB-*Yaa* mice than in BXSB mice. In particular, *Tlr8* expression increased markedly (108-fold, *P* \< 0.001). Semi-quantitative RT-PCR analysis ([Fig. 2b](#f2){ref-type="fig"}) showed that glomerular *Tlr8* expression was higher in BXSB-*Yaa* mice than in BXSB mice at 2 and 4 months of age and that the *Tlr8* band intensity was stronger at 4 months than at 2 months in the glomeruli of BXSB-*Yaa* mice. An increase in glomerular *Tlr8* expression was also observed in B6.MRLc1(68-81) mice, which comprise an autoimmune GN model that we established previously[@b19] ([Supplementary Fig. 1](#s1){ref-type="supplementary-material"}). Because of these findings, we focused on TLR8 in subsequent analyses.

[Figure 2c](#f2){ref-type="fig"} shows the glomerular expression of inflammatory mediators induced by the activation of TLRs[@b13]. The glomerular expression of inflammatory cytokines in the NF-κB pathway, including interleukin 1 beta (*Il1b*)*, Il6*, and tumour necrosis factor (*Tnfa*), was higher in BXSB-*Yaa* mice than in BXSB mice at 4 months of age. In contrast, there were no differences between the strains in the expression of *Nfkb*, transforming growth factor beta (*Tgfb*), and interferon beta 1 (*Ifnb1*).

Localization of TLR8 in mouse and human kidneys
-----------------------------------------------

In immunofluorescence analysis, synaptopodin, a podocyte marker, was detected in the podocyte regions of all examined mice ([Figs. 3a, d, and g](#f3){ref-type="fig"}). However, synaptopodin immunoreactivity was weaker in BXSB-*Yaa* mice ([Fig. 3d](#f3){ref-type="fig"}) than in BXSB and C57BL/6 mice ([Fig. 3a and g](#f3){ref-type="fig"}) at 4 months of age. TLR8 was observed along the glomerular capillary rete, especially in podocyte regions ([Fig. 3b, e, and h](#f3){ref-type="fig"}). The immunoreactivity was stronger in BXSB-*Yaa* mice ([Fig. 3e](#f3){ref-type="fig"}) than in the other two strains ([Fig. 3b and h](#f3){ref-type="fig"}) at 4 months of age. TLR8 co-localized with synaptopodin in the glomeruli of all examined strains ([Fig. 3c, f, and i](#f3){ref-type="fig"}). Although synaptopodin positivity was lower in BXSB-*Yaa* mice ([Fig. 3d](#f3){ref-type="fig"}), we still detected co-localization of synaptopodin with TLR8 ([Fig. 3f](#f3){ref-type="fig"}). As observed in mice, TLR8 co-localized with synaptopodin in healthy human kidneys ([Fig. 3j, k, and l](#f3){ref-type="fig"}).

In *in situ* hybridization analysis of *Tlr8* mRNA, signal was not detected in the glomeruli of BXSB mice ([Fig. 3m](#f3){ref-type="fig"}). In contrast, signal localized to the podocyte region in the glomeruli of BXSB-*Yaa* mice ([Fig. 3n](#f3){ref-type="fig"}).

Correlation between podocyte injury and *Tlr8* mRNA expression in BXSB-*Yaa* mice
---------------------------------------------------------------------------------

The correlations between indices of podocyte injury and *Tlr8* mRNA expression in isolated glomeruli were analysed in BXSB-*Yaa* mice at 4 months of age ([Table 2](#t2){ref-type="table"}). Glomerular *Tlr8* mRNA levels positively correlated with uACR levels, a functional index of glomerular injury, in BXSB-*Yaa* mice (Spearman\'s test, *P* \< 0.01). Furthermore, glomerular *Tlr8* mRNA levels negatively correlated with the glomerular mRNA levels of podocyte functional markers, including nephrin (*Nphs1*), podocin (*Nphs2*), and synaptopodin (*Synpo*), in BXSB-*Yaa* mice.

Glomerular and serum levels of a putative endogenous ligand of TLR8 in BXSB-*Yaa* mice
--------------------------------------------------------------------------------------

A recent study reported that microRNAs, particularly miR-21, act as ligands for TLR8[@b20]. We next examined the glomerular and serum levels of miR-21. miR-21 levels were higher in BXSB-*Yaa* mice than in BXSB mice at 4 months of age ([Fig. 4](#f4){ref-type="fig"}).

Detection of *Tlr8* mRNA in the urine of BXSB-*Yaa* mice
--------------------------------------------------------

The urinary *Tlr8* mRNA levels of BXSB-*Yaa* mice and control mice were determined ([Fig. 5](#f5){ref-type="fig"}). The urinary *Tlr8* levels were higher in BXSB-*Yaa* mice than in BXSB mice at 4 months of age. On the other hand, we detected no difference between serum *Tlr8* levels in BXSB-*Yaa* mice and BXSB mice ([Supplementary Fig. 2](#s1){ref-type="supplementary-material"}).

Discussion
==========

Among glomerular cells, TLRs are expressed by mesangial cells (TLR2--4), endothelial cells (TLR2, 4, 9), and podocytes (TLR1--6, 8, 9)[@b13][@b21]. Pawar *et al*. have demonstrated that the administration of poly (I:C), the ligand for TLR3, aggravates autoimmune GN in MRL/MpJ-*lpr* mice, whereas this ligand does not alter anti-DNA autoantibody levels and does not induce B cell activation[@b22]. According to Fu *et al*., anti-GBM antibody-treated mice develop mild GN, but when the treatment is coupled with specific TLR ligands, including peptidoglycan (TLR2), poly (I:C) (TLR3), LPS (TLR4), or flagellin (TLR5), the treated mice developed GN of greater severity associated with the activation of the NF-κΒ pathway[@b23]. Thus, several *in vivo* studies suggest that TLRs and their exogenous ligands have pathogenic roles in GN[@b13][@b22][@b23].

In the present study, we demonstrated that TLRs, including *Tlr1*, *2*, *7*, *8*, *9,* and *13*, and their downstream factors (*Il1b*, *Il6,* and *Tnfa*) were upregulated through the NF-κΒ pathway in the glomeruli of autoimmune GN mice. From these findings, we concluded that the TLR-mediated NF-κΒ pathway plays an important role in the pathogenesis of autoimmune GN. Importantly, the mRNA expression of TLR family members was induced by major cytokines such as interferon gamma (IFNγ) and TNFα in both inflammatory cells and tissue-intrinsic cells[@b17][@b24]. Experimental and clinical studies have shown that IFNγ and TNFα are upregulated in the serum and kidneys of SLE patients and SLE-prone mice[@b25][@b26]. Indeed, we detected higher levels of glomerular *Tnfa* and *Ifng* in BXSB-*Yaa* mice than in control mice ([Fig. 2c](#f2){ref-type="fig"}). Collectively, these results indicate that local cytokines increased local *Tlr8* expression, especially in podocytes. A previous study showed that *Tlr8* is broadly expressed on myeloid dendritic cells, monocytes, differentiated macrophages, and CD4^+^ regulatory T cells[@b27]. Podocytes might have differential sensitivity to *Tlr8*-inducing cytokines when compared to immunocompetent cells, and this might contribute to the overexpression of glomerular *Tlr8*. Thereby, *Tlr8* overexpression in podocytes would enhance the cells\' responsiveness to their own ligands. These processes might aggravate the pathological conditions of autoimmune GN.

In a previous study, we found that the BXSB-type genome causes SLE-like symptoms and subsequent GN without involvement of *Yaa* and that *Yaa* accelerates disease progression[@b4]. Recently, the *Yaa* mutation was characterized as a translocation from the telomeric end of the X chromosome to the Y chromosome[@b7]. The duplicated segment contains at least 19 genes, including *Tlr7* and *Tlr8*[@b7]. We observed local overexpression of *Tlr7* and *Tlr8* in BXSB-*Yaa* glomeruli; expression of *Tlr8* was markedly increased. Importantly, TLR8 mRNA and protein localized to podocytes in BXSB-*Yaa* mice. Furthermore, the B6.MRLc1(68-81) lupus-prone strain also showed increased glomerular *Tlr8* expression with age. These results suggest that the *Yaa* mutation in addition to the autoimmunity-prone genetic background caused glomerular TLR8 overexpression in BXSB-*Yaa* mice. Although Gurkan *et al*. have reported that *Tlr8* mRNA is expressed in a mouse immortalized podocyte cell line[@b21], our present study demonstrates for the first time that TLR8 protein is expressed by podocytes *in vivo*.

In contrast to TLR8, TLR7 is mainly expressed on infiltrating inflammatory cells, not on renal intrinsic cells, under physiological and pathological conditions[@b13]. In addition to TLR8, podocytes reportedly express several other members of the TLR family, as described above, and recent studies have indicated a pathological correlation between the TLR-mediated NF-κB pathway in podocytes and podocyte injury *in vitro*[@b28][@b29]. Banas *et al*. have shown that TLR4 in podocytes interacts with the innate immune system to mediate glomerular injury[@b28]. Moreover, Machida *et al*. have suggested that TLR9 expression in podocytes is associated with glomerular disease *in vivo*[@b29]. Because of their unique localization in the glomerulus, podocytes are continuously exposed to various plasma solutes containing TLR ligands such as PAMPs and DAMPs. Therefore, podocytes might contribute to renal immunosurveillance by the TLR-mediated immune system.

TLR8 localizes in the endosomal membrane and recognizes single-stranded RNA and short, double-stranded RNA from microbial organisms, leading to the production of a variety of NF-κB-mediated cytokines[@b8]. Several studies have shown that TLR8 also recognizes endogenous miRNAs[@b8]. Although previous studies have demonstrated that secreted miRNAs, which are generally secreted within exosomes, can regulate gene expression in recipient cells via canonical binding to their target mRNAs[@b30], Fabbri *et al*. have shown that exosomal miR-21 and miR-29a can function as ligands for TLR8[@b20]. SLE patients show elevated serum levels of miRNAs, including miR-21[@b1][@b31]. Furthermore, Pan *et al*. have shown that miR-21 is overexpressed in CD4^+^ T cells from patients with lupus and MRL/MpJ-*lpr* mice[@b32]. In the present study, we demonstrated that serum and glomerular miR-21 is overexpressed in autoimmune GN models. These findings indicate that an NF-κB-mediated pathway initiated by the interaction between TLR8 and endogenous ligands, including miR-21, correlates with the pathogenesis of autoimmune GN.

We also found that the glomerular expression of *Tlr8* correlated with the expression of podocyte functional markers and with uACR. These results suggest that the TLR8-mediated pathway closely correlates with podocyte injury. IL-1β, one of the most important cytokines in the NF-κB pathway, is involved in kidney injury; in the glomerulus, IL-1β is mainly produced by podocytes[@b33][@b34]. Furthermore, recent studies have shown that various inflammatory factors, including IL-1β, induce podocyte injury by reducing the production of podocyte functional markers, especially nephrin[@b35][@b36]. We found a strong correlation between the glomerular expression of TLR8-mediated cytokines, including *Il1b*, and the expression of podocyte functional markers ([Supplementary Table 1](#s1){ref-type="supplementary-material"}). Furthermore, our previous study showed that T cells and B cells infiltrate the BXSB-*Yaa* glomerulus as the disease progresses[@b6]. These findings indicate that factors downstream of TLR8, such as IL-1β, directly contribute to podocyte injury and promote the glomerular recruitment of leukocytes in autoimmune GN pathogenesis.

The urinary expression of *Tlr8* mRNA was higher in BXSB-*Yaa* mice than in control mice. A recent study has suggested that glomerular injury in proteinuric renal diseases is strongly associated with the effacement of podocytes caused by disruption of foot processes and/or the slit diaphragm; podocyte mRNA is detected in the urine of patients with renal disease[@b37]. We observed TLR8 expression in human and murine podocytes. Therefore, altered urinary levels of *Tlr8* mRNA might indicate podocyte injury in autoimmune GN.

In conclusion, we showed that members of the TLR family and the TLR8-mediated pathway in particular correlate with podocyte injury in murine autoimmune GN, suggesting that TLR8 is a novel therapeutic and diagnostic target for mouse and human glomerular diseases.

Methods
=======

Ethics statement
----------------

All animal experiments was approved by the Institutional Animal Care and Use Committee, which convenes at the Graduate School of Veterinary Medicine, Hokkaido University (approval No. 13-0032). The investigators adhered to the Guide for the Care and Use of Laboratory Animals of Hokkaido University, Graduate School of Veterinary Medicine (approved by the Association for the Assessment and Accreditation of Laboratory Animal Care International).

Animals
-------

Male BXSB-*Yaa* mice and BXSB mice, which carry the C57BL/6-type Y chromosome on a BXSB-*Yaa* background, were purchased from Japan SLC Inc. (Shizuoka, Japan) and assigned to an autoimmune GN model group or a healthy control group at 2--4 months of age. All mice were maintained under specific pathogen-free conditions. The animals were anesthetized (60 mg/kg pentobarbital sodium, administered intraperitoneally), and urine was collected by bladder puncture. After urine collection, the mice were euthanized by exsanguination from the carotid artery, and the serum, kidneys and spleen were collected.

Sample preparation
------------------

The kidneys were fixed in 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB; pH 7.4) at 4°C for histopathological analysis. PFA-fixed paraffin sections (2-μm-thick) were then prepared and used for PAS staining, PAM staining, or immunofluorescence. For *in situ* hybridization, a portion of the kidneys was embedded in Tissue-Tek OCT Compound (Sakura Finetechnical, Tokyo, Japan). The splenic tissue was stored in RNAlater solution (Life Technologies, Carlsbad, CA, USA) for total RNA isolation.

Human samples
-------------

Normal kidney tissues from autopsied humans without renal disease were obtained from KAC Inc. (Tokyo, Japan). The kidney samples were used for immunofluorescence analysis of TLR8.

Glomerular isolation
--------------------

Murine glomeruli were isolated as previously described[@b6]. Briefly, 40 mL of Hank\'s balanced salt solution (HBSS) containing 8 × 10^7^ Dynabeads (Life Technologies) was perfused from the left ventricle. The kidneys were removed and digested with collagenase A (1 mg/mL; Roche, Basel, Switzerland) and deoxyribonuclease I (100 U/mL; Life Technologies) in HBSS at 37°C for 30 min. The digested tissue was gently pressed through a 100-μm cell strainer (BD Falcon, Franklin Lakes, NJ, USA) using a flattened pestle, and the cell suspension was centrifuged at 200 × *g* for 5 min. The cell pellet was resuspended in 2 mL of HBSS. Finally, glomeruli containing Dynabeads were collected using a magnetic particle concentrator (Life Technologies). The collected glomeruli were used for total RNA isolation.

Serological and urinary analysis
--------------------------------

To evaluate the systemic autoimmune condition, serum levels of anti-dsDNA antibody were measured using the mouse anti-dsDNA Ig (Total A+G+M) ELISA kit (Alpha Diagnostic International, San Antonio, TX, USA). To evaluate renal function, sBUN and sCre levels in all animals were measured using a Fuji Dri-Chem 7000v instrument (Fujifilm, Tokyo, Japan). The uACR was determined using Albuwell M and the Creatinine Companion assay (Exocell, Philadelphia, PA, USA).

*In situ* hybridization
-----------------------

cRNA probes for *Tlr8* were synthesized in the presence of digoxigenin (DIG)-labelled UTP using a DIG RNA Labelling Kit in accordance with the manufacturer\'s protocol (Roche Diagnostics, Mannheim, Germany). The primer pairs for each probe are shown in [Table 3](#t3){ref-type="table"} (product size: 758 bp). Cryosections (6 μm) were treated with acetylation solution and digested with proteinase K. The sections were incubated with a prehybridization solution and then with a hybridization buffer containing 50% formamide, 10 mM Tris-HCl (pH 7.6), 200 mg/mL RNA, 1× Denhardt\'s solution (0.02% bovine serum albumin, 0.02% polyvinylpyrrolidone, and 0.02% Ficoll PM400; Sigma-Aldrich, St. Louis, MO, USA), 10% dextran sulphate, 600 mM NaCl, 0.25% SDS, 1 mM EDTA (pH 8.0), and a sense or antisense RNA probe (final concentration, 0.2 μg/mL) for 24 h at 58°C. After washes in saline sodium citrate buffer, the sections were then incubated with 0.2% polyclonal sheep anti-digoxigenin Fab fragments conjugated to alkaline phosphatase (1: 400; Nucleic Acid Detection Kit, Roche Diagnostics) for 24 h at room temperature. The signal was detected by incubating the sections with a colour substrate solution (Roche Diagnostics) containing nitro blue tetrazolium/X-phosphate in a solution composed of 100 mM Tris-HCl (pH 9.5), 100 mM NaCl, and 50 mM MgCl~2~ in a dark room overnight at room temperature.

Immunofluorescence
------------------

In deparaffinized sections, antigen retrieval was performed in 10 mM citrate buffer at 105°C for 20 min. The sections were washed and blocked with 5% normal donkey serum for 60 min at room temperature. The sections were then incubated with rabbit polyclonal antibodies for TLR8 (1:1000; Abcam, Cambridge, UK) and mouse monoclonal antibodies for synaptopodin (1:50; Fitzgerald, Acton, MA, USA) overnight at 4°C. After washes in PBS, the sections were incubated with Alexa Fluor 546-labelled donkey anti-rabbit IgG antibodies (1:500; Life Technologies) and Alexa Fluor 488-labelled donkey anti-mouse IgG antibodies (1:500; Life Technologies) for 30 min at room temperature and then washed again. For nuclear staining, the sections were incubated with Hoechst 33342 (1:2000; Dojindo, Kumamoto, Japan) for 5 min and examined using a fluorescence microscope (BZ-9000; Keyence, Osaka, Japan).

Reverse transcription and real-time PCR
---------------------------------------

mRNA expression was analysed as previously described[@b6]. Briefly, total RNA was isolated from the glomeruli, spleen, and urine using an RNeasy kit (Qiagen, Hilden, Germany). cDNA was synthesized from total RNA by reverse transcription (RT) using the ReverTra Ace reverse transcriptase enzyme (Toyobo, Osaka, Japan) and random dT primers (Promega). cDNA was used in real-time PCR with Brilliant III SYBR Green QPCR master mix and Mx3000P (Agilent Technologies, La Jolla, CA, USA). Gene expression in the glomeruli and spleen was normalized to the expression of actin, beta (*Actb*). The primer pairs are shown in [Table 3](#t3){ref-type="table"}.

RT- and TaqMan-based real-time PCR
----------------------------------

MicroRNA (miRNA) expression was analysed as described previously[@b19]. Briefly, total RNA including miRNA in the glomeruli and serum was isolated using an miRNeasy kit (Qiagen). Total RNA was reverse-transcribed using miRNA-specific stem-loop RT primers, reverse transcriptase, RT buffer, dNTPs, and RNase inhibitor according to the manufacturer\'s instructions (Applied Biosystems, Foster City, CA, USA). Real-time PCR was performed with the resulting cDNA using miR-21-specific TaqMan primers with specific probes (Applied Biosystems), a TaqMan Universal PCR Master Mix (Applied Biosystems), and Mx3000P (Agilent Technologies).

Statistical analysis
--------------------

The results were expressed as the mean ± standard error (s.e.) and were statistically analysed using a nonparametric Mann-Whitney *U*-test or Welch\'s *t*-test (*P* \< 0.05). The correlation between two parameters was analysed using Spearman\'s rank correlation test (*P* \< 0.05).
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![Glomerular histopathology of BXSB-*Yaa* mice.\
(a--d) Histopathology of glomeruli in periodic acid-Schiff (PAS)-stained sections from BXSB and BXSB-*Yaa* mice. In BXSB mice (a and b), there are no histological differences at the ages of 2 and 4 months. In BXSB-*Yaa* mice (c and d), mesangial matrix expansion and mesangial cell proliferation are clearly observed at 4 months, but not at 2 months. (e--h) Histopathology of glomeruli in periodic acid methenamine silver (PAM)-stained sections from BXSB and BXSB-*Yaa* mice. In BXSB mice (e and f), there are no histological differences at 2 and 4 months. In BXSB-*Yaa* mice (g and h), glomerular hypertrophy, wrinkling of the glomerular basement membrane (GBM), and spike-like structures of the GBM (inset, arrows) are clearly observed at 4 months (h). Bars = 50 μm.](srep07290-f1){#f1}

![mRNA expression of TLR family members and their downstream factors in the glomeruli of BXSB-*Yaa* mice.\
(a) Relative mRNA expression of TLR family genes in isolated glomeruli from BXSB-*Yaa* and BXSB mice at 4 months. The expression levels were normalized to the levels of *Actb*. Values are the mean ± s.e. \*, significantly different from control BXSB mice (Mann-Whitney *U*-test, *P* \< 0.05); n ≥ 4. (b) RT-PCR analysis of *Tlr8* and *Actb* mRNA expression in the glomeruli and spleen of BXSB and BXSB-*Yaa* mice at 4 months of age. n = 2. (c) Relative mRNA expression of *Nfkb*, *Il1b*, *Il6*, *Tgfb*, *Tnfa*, and *Ifnb1* in isolated glomeruli from BXSB-*Yaa* and BXSB mice at 4 months of age. The expression levels were normalized to the levels of *Actb*. The values are the mean ± s.e. \*, significantly different from control BXSB-*Yaa* mice (Mann-Whitney *U*-test, *P* \< 0.05); n ≥ 4.](srep07290-f2){#f2}

![Localization of TLR8 protein and mRNA in the kidneys of mice and humans.\
(a--l) Immunofluorescence of synaptopodin (a, d, g, and j) and TLR8 (b, e, h, and k) in the glomeruli of BXSB (a--c), BXSB-*Yaa* (d--f), and C57BL/6 (g--i) mice and humans (j--l). Merged images are shown (c), (f), (i), and (l). Synaptopodin immunoreactivity (green) co-localized with that of TLR8 (red) (c, f, i, and l). TLR8 positivity in BXSB-*Yaa* mice (e) is stronger than that in BXSB (b) and C57BL/6 (h) mice*.* In the human glomerulus (j--l), TLR8 immunoreactivity co-localizes with synaptopodin immunoreactivity, as in the mouse glomerulus. (m and n) *In situ* hybridization for *Tlr8* mRNA. Positive reactions are observed in the glomeruli of BXSB-*Yaa* cells, especially in podocyte regions (n, arrow). In contrast, no positive reaction is observed in the BXSB glomerulus (m). Bars = 50 μm.](srep07290-f3){#f3}

![Glomerular and serum levels of miR-21.\
The relative glomerular and serum expression of miR-21 in BXSB and BXSB-*Yaa* mice at 4 months of age. Values are the mean ± s.e. Data are presented as the fold increase vs. BXSB in the same samples. \*, significantly different from control BXSB mice (Mann-Whitney *U*-test, *P* \< 0.05); n = 3.](srep07290-f4){#f4}

![Urinary levels of *Tlr8* mRNA.\
Box plots of the relative *Tlr8* mRNA levels in urine from BXSB and BXSB-*Yaa* mice. Values are the mean ± s.e. Data are presented as the fold increase vs. BXSB. \*, significantly different from control BXSB mice (Welch\'s t-test, *P* \< 0.05); n ≥ 4.](srep07290-f5){#f5}

###### Clinical parameters of BXSB and BXSB-*Yaa* mice

                                          dsDNA (μg/mL)                  sBUN (mg/dL)   sCre (mg/dL)                  uACR (μg/mg)
  ------------ ---------- --------------------------------------------- -------------- -------------- ---------------------------------------------
  BXSB          2 months                 148.49 ± 16.07                  17.73 ± 0.13   1.56 ± 0.17                   60.20 ± 9.04
                4 months                 135.43 ± 11.22                  29.80 ± 3.50   0.56 ± 0.03                   47.35 ± 7.40
  BXSB-*Yaa*    2 months   535.15 ± 203.72[\*](#t1-fn3){ref-type="fn"}   20.20 ± 0.28   2.32 ± 1.03                   58.72 ± 9.08
                4 months   890.15 ± 95.44[\*](#t1-fn3){ref-type="fn"}    38.93 ± 9.92   1.30 ± 0.10    439.93 ± 253.78[\*](#t1-fn3){ref-type="fn"}

Values are the mean ± s.e.

dsDNA, double-strand DNA antibody; sBUN, serum blood urea nitrogen; sCre, serum creatinine; uACR, urinary albumin-to-creatinine ratio.

\*Significantly different from BXSB mice at the same age (Mann-Whitney *U*-test, *P* \< 0.05); n ≥ 3.

###### Relationship between glomerular *Tlr8* expression and podocyte injury indices

                                                        Glomerular    Glomerular    Glomerular
  ------------------------------------------ -------- ------------- ------------- -------------
  Spearman\'s rank correlation coefficient    0.847      -0.800        -0.738        -0.801
  *P*-value                                   \<0.01     \<0.01        \<0.01        \<0.01

The mRNA expression of podocyte functional markers *Nphs1*, *Nphs2*, and *Synpo* in BXSB/MpJ-*Yaa* mice at 4 months was quantified using real-time PCR. n ≥ 5.

uACR: urinary albumin creatinine ratio.

###### Summary of gene-specific primers

  Gene              Primer sequence (5′--3′)     Product size         Application
  --------------- ----------------------------- -------------- -------------------------
  *Tlr1*            F: GTGAATGCAGTTGGTGAAGAAC        125             Real-time PCR
  (NM_030682)       R: ATGGCCATAGACATTCCTGAG                                
  *Tlr2*             F: GAGCATCCGAATTGCATCA          163             Real-time PCR
  (NM_011905)       R: CACATGACAGAGACTCCTGAGC                               
  *Tlr3*            F: GATACAGGGATTGCACCCATA         122             Real-time PCR
  (NM_126166)       R: GCATTGGTTTGTGGAAGACAC                                
  *Tlr4*            F: TTCAGAACTTCAGTGGCTGGA         115             Real-time PCR
  (NM_021297)       R: CTGGATAGGGTTTCCTGTCAGT                               
  *Tlr5*            F: ATGCCAGACACATCTGTGAGA         177             Real-time PCR
  (NM_016928)        R: ATCCTGCCGTCTGAAGAACA                                
  *Tlr6*             F: ATGGTACCGTCAGTGCTGGA         104             Real-time PCR
  (NM_011604)        R: TCTGTCTTGGCTCATGTTGC                                
  *Tlr7*            F: TGACTCTCTTCTCCTCCACCAG        198             Real-time PCR
  (NM_133211)        R: TCTGTGCAGTCCACGATCAC                                
  *Tlr8*           F: GTTATGTTGGCTGCTCTGGTTCAC       203             Real-time PCR
  (NM_133212)       R: TCACTCTCTTCAAGGTGGTAGC                               
  *Tlr8*           F: ATGGAAAACATGCCCCCTCAGTC        758        *in situ* hybridization
  (NM_133212)      R: GGACAGTTTCCACTCAGATCTAG                               
  *Tlr9*             F: GAATCCTCCATCTCCCAACA         181             Real-time PCR
  (NM_031178)       R: GGGTACAGACTTCAGGAACAGC                               
  *Tlr11*            F: CACCATTGTGGAGGGAAGAG         158             Real-time PCR
  (NM_205819)       R: TCAGAATGAGGAGAACAGAGCA                               
  *Tlr12*            F: GAACTTCTGCCTGCTCTGGA         146             Real-time PCR
  (NM_205823)        R: AACACGCAGAGTGTGGTACG                                
  *Tlr13*            F: TCCTCTGTTGCATGATGTCG         182             Real-time PCR
  (NM_205820.1)    R: CTGTCTTAGGCATCCAGGTTACA                               
  *Nphs1*           F: ACCTGTATGACGAGGTGGAGAG        218             Real-time PCR
  (NM_019459)       R: TCGTGAAGAGTCTCACACCAG                                
  *Nphs2*           F: AAGGTTGATCTCCGTCTCCAG         105             Real-time PCR
  (NM_130456)       R: TTCCATGCGGTAGTAGCAGAC                                
  *Synpo*            F: CATCGGACCTTCTTCCTGTG          90             Real-time PCR
  (NM_177340.2)       R: TCGGAGTCTGTGGGTGAG                                 
  *Nfkb*             F: GGAGTTTGACGGTCGTGAG          219             Real-time PCR
  (NM008689)         R: GGGCCTTCACACACATAGC                                 
  *Il1b*             F: AAGGAGAACCAAGCAACGAC         208             Real-time PCR
  (NM008361)       R: AACTCTGCAGACTCAAACTCCAC                               
  *Il6*             F: TGTATGAACAACGATGATGCAC        137             Real-time PCR
  (NM031168)        R: TGGTACTCCAGAAGACCAGAGG                               
  *Tgfb*            F: AGCCTGGACACACAGTACAGC         125             Real-time PCR
  (NM011577)        R: CGACCCACGTAGTAGACGATG                                
  *Tnfa*             F: CGAGTGACAAGCCTGTAGCC         167             Real-time PCR
  (NM013693)        R: GAGAACCTGGGAGTAGACAAGG                               
  *Ifnb1*           F: CAGCTCCAAGAAAGGACGAAC         138             Real-time PCR
  (NM010510.1)      R: GGCAGTGTAACTCTTCTGCAT                                
  *Ifng*             F: CCTTTGGACCCTCTGACTTG         201             Real-time PCR
  (NM008337.3)      R: TTCCACATCTATGCCACTTGAG                               
  *Actb*             F: TGTTACCAACTGGGACGACA         165             Real-time PCR
  (NM007393)         R: GGGGTGTTGAAGGTCTCAAA                                
